| Fri, Dec 18, 2009 | | • | 3 Reasons to Buy Dendreon Today
at Motley Fool (Fri, Dec 18)
| | • | Celgenes Surprising New Hope for Blood Cancer
at Minyanville.com (Fri, Dec 18)
| | Wed, Dec 16, 2009 | | • | ONYX Pharmaceuticals, Inc. (ONXX) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
GlobeNewswire (Wed, Dec 16)
| | Fri, Dec 11, 2009 | | • | Nexavar may help breast cancer drugs work longer
at Reuters (Fri, Dec 11)
| | • | Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
PR Newswire (Fri, Dec 11)
| | • | Remember The Alamo Embargo
at CNBC (Fri, Dec 11)
| | Thu, Dec 10, 2009 | | • | Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
PR Newswire (Thu, Dec 10)
| | Wed, Dec 9, 2009 | | • | Positive Data from Onyx
Zacks.com (Wed, Dec 9)
| | Mon, Dec 7, 2009 | | • | Biotechs to Watch in the Blood Business
at Minyanville.com (Mon, Dec 7)
| | • | When the Big Guns Come In, You Get Blasted
at Motley Fool (Mon, Dec 7)
| | • | UPDATE - Onyx drug shows promise in multiple myeloma study
at Reuters (Mon, Dec 7)
| | • | Carfilzomib Data Demonstrate Promising Efficacy and Tolerability Signals in Ongoing Phase 1b/2 Combination Study with Lenalidomide and Low Dose Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
PR Newswire (Mon, Dec 7)
| | • | Carfilzomib Demonstrates Encouraging Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma in an Ongoing Phase 2 Study
PR Newswire (Mon, Dec 7)
| | Sun, Dec 6, 2009 | | • | Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
PR Newswire (Sun, Dec 6)
| | Fri, Dec 4, 2009 | | • | Cramer's 'Mad Money' Recap: How to Play the Surprising Jobs Report (Update 1)
at TheStreet.com (Fri, Dec 4)
| | • | The Coming Week's Game Plan: Blood, Tech and Jeers
at CNBC (Fri, Dec 4)
| | • | Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
PR Newswire (Fri, Dec 4)
| | Thu, Dec 3, 2009 | | • | Coverage initiated on Onyx Pharma by Soleil
Briefing.com (Thu, Dec 3)
| | Wed, Dec 2, 2009 | | • | S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
PR Newswire (Wed, Dec 2)
| | Wed, Nov 25, 2009 | | • | Onyx Pharmaceuticals Announces December 2009 Investor Events
PR Newswire (Wed, Nov 25)
|
Add ONXX News to My Yahoo!:
 
| |
|
0.49% Nasdaq 0.00%
Headlines
